Establishing a relationship between prolactin and altered fatty acid β-Oxidation via carnitine palmitoyl transferase 1 in breast cancer cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Linher Melville, Katja ^a   Zantinge, Stephanie ^a   Sanli, Toran ^a   Gerstein, Hertzel ^a   Tsakiridis, Theodoros ^a   Singh, Gurmit ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CARNITINE PALMITOYLTRANSFERASE I; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER ENZYME; LIVER KINASE B1; MESSENGER RNA; PROLACTIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CARNITINE PALMITOYLTRANSFERASE; PRKAA1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; RECOMBINANT PROTEIN; STK11 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; BREAST TUMOR; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENE SILENCING; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; PHOSPHORYLATION; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; BREAST NEOPLASMS; CARNITINE O-PALMITOYLTRANSFERASE; CELL LINE, TUMOR; FATTY ACIDS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; OXIDATION-REDUCTION; PHOSPHORYLATION; PROLACTIN; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 79551591488     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-56     Document Type: Article

References (53)

1. Binart N, Ormandy CJ, Kelly PA. Mammary gland development and the prolactin receptor. Adv Exp Med Biol 2000, 480:85-92. full_text, 10959413.
2. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003, 24(1):1-27. 10.1210/er.2001-0036, 1698952, 12588805.
3. Anderson E, Ferguson JE, Morten H, Shalet SM, Robinson EL, Howell A. Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. Eur J Cancer 1993, 29A(2):209-217. 10.1016/0959-8049(93)90178-I, 8422285.
4. Fields K, Kulig E, Lloyd RV. Detection of prolactin messenger RNA in mammary and other normal and neoplastic tissues by polymerase chain reaction. Lab Invest 1993, 68(3):354-360.
5. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 1995, 146(3):695-705. 1869171, 7534043.
6. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995, 55(12):2591-2595.
7. Ramamoorthy P, Sticca R, Wagner TE, Chen WY. In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. Int J Oncol 2001, 18(1):25-32.
8. Rudolph MC, Neville MC, Anderson SM. Lipid synthesis in lactation: diet and the fatty acid switch. J Mammary Gland Biol Neoplasia 2007, 12(4):269-281. 10.1007/s10911-007-9061-5, 18027074.
9. Anderson SM, Rudolph MC, McManaman JL, Neville MC. Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis!. Breast Cancer Res 2007, 9(1):204. 10.1186/bcr1653, 1851396, 17338830.
10. Mao J, Molenaar AJ, Wheeler TT, Seyfert HM. STAT5 binding contributes to lactational stimulation of promoter III expressing the bovine acetyl-CoA carboxylase alpha-encoding gene in the mammary gland. J Mol Endocrinol 2002, 29(1):73-88. 10.1677/jme.0.0290073, 12200230.
11. Nilsson LA, Roepstorff C, Kiens B, Billig H, Ling C. Prolactin suppresses malonyl-CoA concentration in human adipose tissue. Horm Metab Res 2009, 41(10):747-751. 10.1055/s-0029-1224181, 19551610.
12. Hogan JC, Stephens JM. The regulation of fatty acid synthase by STAT5A. Diabetes 2005, 54(7):1968-1975. 10.2337/diabetes.54.7.1968, 15983196.
13. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006, 574(Pt 1):63-71. 10.1113/jphysiol.2006.108324, 1817805, 16613876.
14. Ha J, Daniel S, Broyles SS, Kim KH. Critical phosphorylation sites for acetyl-CoA carboxylase activity. J Biol Chem 1994, 269(35):22162-22168.
15. Murthy MS, Pande SV. Some differences in the properties of carnitine palmitoyltransferase activities of the mitochondrial outer and inner membranes. Biochem J 1987, 248(3):727-733. 1148610, 3435481.
16. Murthy MS, Pande SV. Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane. Proc Natl Acad Sci USA 1987, 84(2):378-382. 10.1073/pnas.84.2.378, 304210, 3540964.
17. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 1997, 244(1):1-14. 10.1111/j.1432-1033.1997.00001.x, 9063439.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
19. Bieber LL, Abraham T, Helmrath T. A rapid spectrophotometric assay for carnitine palmitoyltransferase. Anal Biochem 1972, 50(2):509-518. 10.1016/0003-2697(72)90061-9, 4630394.
20. Karlic H, Lohninger S, Koeck T, Lohninger A. Dietary l-carnitine stimulates carnitine acyltransferases in the liver of aged rats. J Histochem Cytochem 2002, 50(2):205-212.
21. Shin ES, Cho SY, Lee EH, Lee SJ, Chang IS, Lee TR. Positive regulation of hepatic carnitine palmitoyl transferase 1A (CPT1A) activities by soy isoflavones and L-carnitine. Eur J Nutr 2006, 45(3):159-164. 10.1007/s00394-005-0576-5, 16362726.
22. Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC, Singh G, Wright J, Tsakiridis T. Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys 78(1):221-229.
23. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003, 2(4):28. 10.1186/1475-4924-2-28, 333410, 14511394.
24. Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 1804(3):581-591.
25. Harper ME, Antoniou A, Villalobos-Menuey E, Russo A, Trauger R, Vendemelio M, George A, Bartholomew R, Carlo D, Shaikh A, et al. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. Faseb J 2002, 16(12):1550-1557. 10.1096/fj.02-0541com, 12374777.
26. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120(1):142-156. 10.1172/JCI38942, 2799198, 20038799.
27. Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 1997, 3(11):2115-2120.
28. Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE, Kuhajda FP. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 1996, 56(12):2745-2747.
29. Puig T, Vazquez-Martin A, Relat J, Petriz J, Menendez JA, Porta R, Casals G, Marrero PF, Haro D, Brunet J, et al. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res Treat 2008, 109(3):471-479. 10.1007/s10549-007-9678-5, 17902053.
30. Mazzarelli P, Pucci S, Bonanno E, Sesti F, Calvani M, Spagnoli LG. Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation?. Cancer Biol Ther 2007, 6(10):1606-1613. 10.4161/cbt.6.10.4742, 18253084.
31. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000, 16(3):202-208. 10.1016/S0899-9007(99)00266-X, 10705076.
32. Baron A, Migita T, Tang D, Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer?. J Cell Biochem 2004, 91(1):47-53. 10.1002/jcb.10708, 14689581.
33. Bruce CR, Brolin C, Turner N, Cleasby ME, van der Leij FR, Cooney GJ, Kraegen EW. Overexpression of carnitine palmitoyltransferase I in skeletal muscle in vivo increases fatty acid oxidation and reduces triacylglycerol esterification. Am J Physiol Endocrinol Metab 2007, 292(4):E1231-1237. 10.1152/ajpendo.00561.2006, 17179390.
34. Weinstein I, Cook GA, Heimberg M. Regulation by oestrogen of carnitine palmitoyltransferase in hepatic mitochondria. Biochem J 1986, 237(2):593-596. 1147025, 3800903.
35. O'Sullivan AJ, Crampton LJ, Freund J, Ho KK. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 1998, 102(5):1035-1040. 508969, 9727072.
36. O'Sullivan AJ, Hoffman DM, Ho KK. Estrogen, lipid oxidation, and body fat. N Engl J Med 1995, 333(10):669-670.
37. Hardie DG, Scott JW, Pan DA, Hudson ER. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 2003, 546(1):113-120. 10.1016/S0014-5793(03)00560-X, 12829246.
38. Kemp BE, Stapleton D, Campbell DJ, Chen ZP, Murthy S, Walter M, Gupta A, Adams JJ, Katsis F, van Denderen B, et al. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 2003, 31(Pt 1):162-168.
39. Hardie DG. Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase. Biochim Biophys Acta 1992, 1123(3):231-238.
40. Park H, Kaushik VK, Constant S, Prentki M, Przybytkowski E, Ruderman NB, Saha AK. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem 2002, 277(36):32571-32577. 10.1074/jbc.M201692200, 12065578.
41. Ferre P, Azzout-Marniche D, Foufelle F. AMP-activated protein kinase and hepatic genes involved in glucose metabolism. Biochem Soc Trans 2003, 31(Pt 1):220-223.
42. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase--development of the energy sensor concept. J Physiol 2006, 574(Pt 1):7-15. 10.1113/jphysiol.2006.108944, 1817788, 16644800.
43. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG, Hardie DG. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005, 2(1):9-19. 10.1016/j.cmet.2005.05.009, 16054095.
44. Xie M, Zhang D, Dyck JR, Li Y, Zhang H, Morishima M, Mann DL, Taffet GE, Baldini A, Khoury DS, et al. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci USA 2006, 103(46):17378-17383. 10.1073/pnas.0604708103, 1859937, 17085580.
45. Woods A, Azzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P, Foufelle F, Carling D. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol 2000, 20(18):6704-6711. 10.1128/MCB.20.18.6704-6711.2000, 86183, 10958668.
46. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108(8):1167-1174. 209533, 11602624.
47. Yang W, Hong YH, Shen XQ, Frankowski C, Camp HS, Leff T. Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors. J Biol Chem 2001, 276(42):38341-38344. 10.1074/jbc.C100316200, 11518699.
48. Yoon M. The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. Pharmacol Res 2009, 60(3):151-159. 10.1016/j.phrs.2009.02.004, 19646654.
49. Tachibana K, Kobayashi Y, Tanaka T, Tagami M, Sugiyama A, Katayama T, Ueda C, Yamasaki D, Ishimoto K, Sumitomo M, et al. Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. Nucl Recept 2005, 3:3. 10.1186/1478-1336-3-3, 1262764, 16197558.
50. Carver KC, Arendt LM, Schuler LA. Complex prolactin crosstalk in breast cancer: new therapeutic implications. Mol Cell Endocrinol 2009, 307(1-2):1-7. 10.1016/j.mce.2009.03.014, 19524120.
51. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314. 10.1126/science.123.3191.309, 13298683.
52. Paumen MB, Ishida Y, Muramatsu M, Yamamoto M, Honjo T. Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. J Biol Chem 1997, 272(6):3324-3329. 10.1074/jbc.272.6.3324, 9013572.
53. Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, Panaretakis T, Shoshan MC. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 2008, 123(2):476-483. 10.1002/ijc.23525, 18452174.